Level of S100A4 mRNA in endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) biopsies is reported to be a predictive molecular biomarker for chemosensitivity to the first-line chemotherapy of Gemcitabine in patients with unresectable pancreatic cancer [119], and can also be used to predict poor response of pancreatic cancer to radiation therapy [120]. This evidence concerns the gene S100A4 and pancreatic neoplasm.